Molding topologically-complex 3D polymer microstructures from femtosecond laser machined glass

The fabrication of complex, three-dimensional microscale shapes that can be replicated over large surfaces is an ongoing challenge, albeit one with a wide range of possible applications such as engineered surfaces with tuned wetting properties, scaffolds for cell studies, or surfaces with tailored optical properties. In this work, we use a two-step femtosecond laser direct-write technique and wet-etching process to fabricate monolithic glass micromolds with complex three-dimensional surface topologies, and demonstrate the replication of these structures in a soft polymer (polydimethylsiloxane, PDMS). To estimate the forces experienced during the demolding for one representative structure, we use a combination of two models – a simple linear elastic model and a numerical hyperelastic model. These models are used to support the high experimental success rates of the demolding process observed, despite the high strain induced in the material during demolding. Since the process used is scalable, this work opens new avenues for low-cost fabrication of surfaces having complex microscale patterns with three-dimensional geometries

Sorting algal cells by morphology in spiral microchannels using inertial microfluidics

Sub-millimetre phytoplankton (here referred to as algae) exist in a wide variety of shapes and sizes. Measuring algae morphology can be a useful tool for understanding the species dynamics in a body of water, and size-sorting in general is a valuable first step in automated species identification. Here, we demonstrate the sorting of algae by shape and size in a spiral microchannel, in which lift forces and Dean flow drag forces combine to position the cells in a shape-dependent location in the channel cross section. Three species were used for experiments: the high-aspect-ratio cylindrical Monoraphidium griffithii, the prolate spheroidal Cyanothece aeruginosa, and the small spherical Chlorella vulgaris. These results are compared with the sorting of similarly sized polystyrene latex microspheres in the same device over the same range of flow rates. Tests were done at conditions which yielded average Dean numbers over the channel length of 3 < De < 30. At 1.6 mL/min, the 10- and 20-µm microspheres could be separated with an efficiency of 96 %. The best sorting results for the algae were obtained at a flow rate of 3.2 mL/min, which yielded an average Dean number of De = 25 over the channel length. These conditions led to the separation of the Monoraphidium from the differently shaped Cyanothece; these two species could be sorted with a 77 % separation efficiency despite the relatively high polydispersity in cell sizes within each species. The elegance and simplicity of inertial microfluidics make it appropriate for the high-throughput pre-sorting of algae cells upstream of other integrated sensing modalities in a field-deployable device

Enhancement of microalgae growth using magnetic artificial cilia

Microalgae have shown great potential as a source of biofuels, food, and other bioproducts. More recently, microfluidic devices have been employed in microalgae-related studies. However, at small fluid volumes, the options for controlling flow conditions are more limited and mixing becomes largely reliant on diffusion. In this study, we fabricated magnetic artificial cilia (MAC) and implemented them in millimeter scale culture wells and conducted growth experiments with Scenedesmus subspicatus while actuating the MAC in a rotating magnetic field to create flow and mixing. In addition, surface of MAC was made hydrophilic using plasma treatment and its effect on growth was compared with untreated, hydrophobic MAC. The experiments showed that the growth was enhanced by ten and two times with hydrophobic and hydrophilic MAC, respectively, compared with control groups which contain no MAC. This technique can be used to investigate mixing and flow in small sample volumes, and the enhancement in growth can be beneficial for the throughput of screening studies. Moreover, the methods used for creating and controlling MAC can be easily adopted in labs without microfabrication infrastructures, and they can be mastered by people with little prior experience in microfluidics

Quantification of a subsea CO2 release with lab-on-chip sensors measuring benthic gradients

We present a novel approach to detecting and quantifying a subsea release of CO2 from within North Sea sediments, which mimicked a leak from a subsea CO2 reservoir. Autonomous lab-on-chip sensors performed in situ measurements of pH at two heights above the seafloor. During the 11 day experiment the rate of CO2 release was gradually increased. Whenever the currents carried the CO2-enriched water towards the sensors, the sensors measured a decrease in pH, with a strong vertical gradient within a metre of the seafloor. At the highest release rate, a decrease of over 0.6 pH units was observed 17 cm above the seafloor compared to background measurements. The sensor data was combined with hydrodynamic measurements to quantify the amount of CO2 escaping the sediments using an advective mass transport model. On average, we directly detected 43 ± 8% of the released CO2 in the water column. Accounting for the incomplete carbonate equilibration process increases this estimate to up to 61 ± 10%. This technique can provide long-term in situ monitoring of offshore CO2 reservoirs and hence provides a tool to support climate change mitigation activities. It could also be applied to characterising plumes and quantifying other natural or anthropogenic fluxes of dissolved solutes

Detection and quantification of CO2 seepage in seawater using the stoichiometric Cseep method:Results from a recent subsea CO2 release experiment in the North Sea

Carbon Capture and Storage (CCS) is a potential significant mitigation strategy to combat climate change and ocean acidification. The technology is well understood but its current implementation must be scaled up nearly by a hundredfold to become an effective tool that helps meet mitigation targets. Regulations require monitoring and verification at storage sites, and reliable monitoring strategies for detection and quantification of seepage of the stored carbon need to be developed. The Cseep method was developed for reliable determination of CO2 seepage signal in seawater by estimating and filtering out natural variations in dissolved inorganic carbon (C). In this work, we analysed data from the first-ever subsea CO2 release experiment performed in the north-western North Sea by the EU STEMM−CCS project. We successfully demonstrated the ability of the Cseep method to (i) predict natural C variations around the Goldeneye site over seasonal to interannual time scales; (ii) establish a process-based baseline C concentration with minimal variability; (iii) determine CO2 seepage detection threshold (DT) to reliably differentiate released−CO2 signal from natural variability and quantify released−CO2 dissolved in the sampled seawater. DT values were around 20 % of the natural C variations indicating high sensitivity of the method. Moreover, with the availability of DT value, the identification of released−CO2 required no pre-knowledge of seepage occurrence, but we used additional available information to assess the confidence of the results. Overall, the Cseep method features high sensitivity, automation suitability, and represents a powerful future monitoring tool both for large and confined marine areas

Unlocking the potential of sensors for our environment:A call to action from a NERC writing retreat

Funded by NERC Constructed for the Digital Environment, the report is a culmination of an intensive co-creation process and writing retreat that brought together experts in the field of environmental sensing to explore how to accelerate advancements in environmental sensing and sensor networks that acknowledge and respond to the interconnections between people, places, and ethics. The report emerges as a foundational document aimed at guiding future funding calls, stimulating innovation, and advocating for interdisciplinary research approaches

Lab-on-chip for in situ analysis of nutrients in the deep sea

Microfluidic reagent-based nutrient sensors offer a promising technology to address the global undersampling of ocean chemistry but have so far not been shown to operate in the deep sea (>200 m). We report a new family of miniaturized lab-on-chip (LOC) colorimetric analyzers making in situ nitrate and phosphate measurements from the surface ocean to the deep sea (>4800 m). This new technology gives users a new low-cost, high-performance tool for measuring chemistry in hyperbaric environments. Using a combination of laboratory verification and field-based tests, we demonstrate that the analyzers are capable of in situ measurements during profiling that are comparable to laboratory-based analyses. The sensors feature a novel and efficient inertial-flow mixer that increases the mixing efficiency and reduces the back pressure and flushing time compared to a previously used serpentine mixing channel. Four separate replicate units of the nitrate and phosphate sensor were calibrated in the laboratory and showed an average limit of detection of 0.03 μM for nitrate and 0.016 μM for phosphate. Three on-chip optical absorption cell lengths provide a large linear range (to >750 μM (10.5 mg/L-N) for nitrate and >15 μM (0.47 mg/L-P) for phosphate), making the instruments suitable for typical concentrations in both ocean and freshwater aquatic environments. The LOC systems automatically collected a series of deep-sea nitrate and phosphate profiles in the northeast Atlantic while attached to a conductivity temperature depth (CTD) rosette, and the LOC nitrate sensor was attached to a PROVOR profiling float to conduct automated nitrate profiles in the Mediterranean Sea

Validation of sensor and instrumentation innovations

Validated prototypes of new and enhanced biogeochemical and biological sensors and instruments. Validation will be undertaken in the laboratory, in test scenarios, and by deployment in operational condition

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction&gt;0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk